HC Wainwright & Co. Maintains Buy on CymaBay Therapeutics, Raises Price Target to $19
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Ed Arce maintains a 'Buy' rating on CymaBay Therapeutics (NASDAQ:CBAY) and raises the price target from $12 to $19.
August 01, 2023 | 10:20 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CymaBay Therapeutics' price target has been raised from $12 to $19 by HC Wainwright & Co., with a maintained 'Buy' rating.
The raised price target and maintained 'Buy' rating by HC Wainwright & Co. indicates a positive outlook for CymaBay Therapeutics. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100